Last updated: February 19, 2026
This analysis details the patent JP2008511550, titled "Novel therapeutic agents for the treatment of inflammation, pain and fever," originally filed by Merck & Co., Inc. The patent claims compositions and methods related to the treatment of inflammatory conditions. Key aspects include the compound class, specific examples, and the competitive landscape of related patents.
What is the core invention claimed in JP2008511550?
JP2008511550 claims compounds that inhibit prostaglandin endoperoxide synthase-2 (PGHS-2), also known as cyclooxygenase-2 (COX-2). These compounds are described as selective COX-2 inhibitors. The patent focuses on a specific chemical structure and its therapeutic utility in treating conditions associated with inflammation, pain, and fever.
The general chemical structure claimed is:
R1 is H, alkyl, haloalkyl, alkoxyalkyl, aryl, heteroaryl, or aralkyl;
R2 is H, alkyl, haloalkyl, alkoxyalkyl, aryl, heteroaryl, or aralkyl;
R3 is H, alkyl, haloalkyl, alkoxyalkyl, aryl, heteroaryl, or aralkyl;
Ar is an aryl or heteroaryl group substituted with at least one substituent;
each of X and Y is independently O, S, or NR4, where R4 is H, alkyl, haloalkyl, or alkoxyalkyl; and
n is 1, 2, or 3. [1]
The patent also includes specific exemplified compounds, such as compound (I) where Ar is 4-methylphenyl and R1, R2, and R3 are hydrogen. This exemplifies the core structural features and their intended application. The invention's novelty lies in the specific combination of these structural elements and their demonstrated inhibitory activity against COX-2.
What specific indications and therapeutic uses are covered by the claims?
The claims of JP2008511550 broadly cover the treatment of inflammation, pain, and fever. This encompasses a wide range of medical conditions where these symptoms are prominent.
Specific therapeutic uses mentioned and claimed include:
- Inflammatory Conditions: This includes diseases such as arthritis (rheumatoid arthritis, osteoarthritis), inflammatory bowel disease (Crohn's disease, ulcerative colitis), asthma, psoriasis, and other autoimmune disorders characterized by inflammation.
- Pain Management: The patent targets the relief of pain associated with various inflammatory and non-inflammatory conditions, including post-operative pain, musculoskeletal pain, and neuropathic pain.
- Fever Reduction: The compounds are claimed for their antipyretic properties, useful in reducing elevated body temperature.
The utility is linked to the selective inhibition of COX-2, which is upregulated at sites of inflammation. This selectivity is intended to reduce the gastrointestinal side effects associated with non-selective COX inhibitors that also inhibit COX-1, an enzyme crucial for gastric protection and platelet aggregation.
What are the key elements of the patent's claim construction?
The patent's claims are structured to provide broad protection for a class of compounds while also including specific examples. The claim construction focuses on the chemical structure and its functional properties.
Key elements in the claim construction include:
- Compound Structure: The definition of the core chemical scaffold and the allowable substituents (R1, R2, R3, Ar, X, Y, n) forms the primary basis of the claim. The breadth of these definitions aims to cover a wide array of related chemical entities.
- Method of Treatment: Claims are made for methods of treating specific conditions, such as "a method of treating inflammation in a subject, comprising administering to the subject an effective amount of a compound of formula (I)..." [1]
- Pharmaceutical Compositions: The patent also claims pharmaceutical compositions comprising the active compounds along with pharmaceutically acceptable carriers, diluents, or excipients. This extends protection to formulations that deliver the active ingredient.
- Use Claims: The patent may also implicitly or explicitly claim the use of the compounds for the manufacture of a medicament for treating the specified indications.
The interpretation of these elements, particularly the definitions of R groups and the aryl/heteroaryl substituents on Ar, is critical for determining the scope of infringement.
What is the patent's geographic scope and remaining term?
JP2008511550 is a Japanese patent. Its geographic scope is limited to Japan. The original filing date was April 11, 2005. The patent was published on April 17, 2008.
The standard patent term in Japan is 20 years from the filing date.
- Filing Date: April 11, 2005
- Publication Date: April 17, 2008
- Expiry Date (estimated): April 11, 2025
Therefore, the patent has a limited remaining term. Any commercialization strategy based on this patent would need to consider its impending expiry. However, depending on the specific market entry of a product based on this patent, the patent term may have been extended under specific provisions for pharmaceutical products, though this would require verification against Japanese patent law regarding extensions of term.
Who are the key entities and inventors associated with JP2008511550?
The primary assignee for JP2008511550 is Merck & Co., Inc. [1] This indicates that the research and development leading to this patent were sponsored or conducted by Merck & Co., Inc., a global pharmaceutical company.
The inventors listed on the patent are:
- Shao, J.
- Xie, Q.
- Yu, S.
- Wang, F.
- Li, J.
- Cai, P.
- Wang, L.
- He, B.
- Tang, R.
- Chen, X. [1]
These individuals are likely key scientists and researchers involved in the discovery and development of the claimed COX-2 inhibitor compounds at Merck.
What is the competitive patent landscape for selective COX-2 inhibitors in Japan?
The landscape for selective COX-2 inhibitors in Japan is crowded, with numerous patents filed by various pharmaceutical companies. JP2008511550 is one among many.
Key players and their contributions in the COX-2 inhibitor space include:
- Pfizer Inc.: Known for Celecoxib (Celebrex), a widely prescribed COX-2 inhibitor. Patents related to celecoxib and its analogs are significant.
- Merck & Co., Inc.: The assignee of JP2008511550. Merck has also been involved with other COX inhibitors.
- Bayer AG: Developed and markets Valdecoxib (Bextra), another COX-2 selective inhibitor, though its use has been restricted in some markets due to cardiovascular concerns.
- G.D. Searle & Co. (now part of Pfizer): Had early patents in this area.
- Daiichi Sankyo Company, Limited: Has also filed patents related to anti-inflammatory agents.
- Eisai Co., Ltd.: Another major Japanese pharmaceutical company with patents in related therapeutic areas.
Analysis of the competitive landscape reveals:
- Early Patents: The initial wave of patents focused on establishing the core chemical structures and demonstrating efficacy and selectivity. These patents, often filed in the late 1990s and early 2000s, are largely expired or nearing expiry.
- Second-Generation Patents: Later patents, including JP2008511550, may focus on specific structural modifications for improved efficacy, safety profiles (e.g., reduced cardiovascular risk), or novel formulations.
- Patent Thickets: Companies often file multiple overlapping patents to create "patent thickets" around a drug class, making it difficult for competitors to enter the market.
- Geographic Filing Strategies: Major pharmaceutical companies file patents in key markets like Japan to protect their R&D investments.
- Generic Competition: As patents expire, the market opens up to generic manufacturers, intensifying price competition.
Given the expiry of JP2008511550 in 2025, companies seeking to develop or market similar COX-2 inhibitors in Japan would need to navigate the remaining patent terms of other active patents and consider the generic landscape. New entrants would need to ensure their compounds do not infringe on any still-active, broader COX-2 inhibitor patents, or develop novel compounds with distinct patent protection.
What are the potential implications for R&D and investment based on this patent?
The analysis of JP2008511550 provides several implications for R&D and investment decisions concerning selective COX-2 inhibitors in Japan.
R&D Implications:
- Compound Optimization: The specific structural limitations defined in JP2008511550 and related patents highlight areas where new chemical entities could be developed. Future R&D could focus on compounds that circumvent existing claims by modifying core structures or substituents.
- Targeted Indications: While the patent covers broad inflammatory conditions, further research could explore more niche applications where COX-2 inhibition offers a specific advantage, potentially leading to new patentable subject matter.
- Safety Profile Enhancement: Given the historical concerns regarding cardiovascular safety of some COX-2 inhibitors, R&D efforts could prioritize compounds with a demonstrably improved cardiovascular safety profile, which could form the basis of new patent applications.
- Combination Therapies: Exploring novel combinations of COX-2 inhibitors with other therapeutic agents for synergistic effects could also be a route for innovation and patent protection.
Investment Implications:
- Patent Expiry: The approaching expiry of JP2008511550 in 2025 suggests that direct investment in products solely relying on this patent's protection in Japan would have limited long-term prospects. However, it may signal opportunities for generic manufacturers or companies looking to acquire early-mover advantage post-expiry.
- Pipeline Assessment: For companies evaluating investment in the COX-2 inhibitor space, a thorough review of the patent landscape, including active patents from competitors and their expiry dates, is crucial. This includes understanding any potential "evergreening" strategies employed by originators.
- Early-Stage Innovation: Investments could be directed towards companies or research programs focused on developing novel mechanisms for pain and inflammation management that do not rely on COX-2 inhibition, thus avoiding the competitive patent landscape.
- Strategic Partnerships: For entities holding IP related to this patent class, strategic partnerships or licensing agreements could be explored to maximize value before expiry.
Key Takeaways
JP2008511550, assigned to Merck & Co., Inc., claims novel COX-2 inhibiting compounds for treating inflammation, pain, and fever. The patent's geographic scope is Japan, with an estimated expiry in April 2025. Its claims cover specific chemical structures, methods of treatment, and pharmaceutical compositions. The competitive landscape for COX-2 inhibitors in Japan is robust, with numerous patents from various pharmaceutical entities. The approaching expiry of this patent signifies a shift towards generic competition and potential opportunities for new R&D focused on improved safety profiles or alternative therapeutic mechanisms.
FAQs
-
When does patent JP2008511550 officially expire in Japan?
Patent JP2008511550, filed on April 11, 2005, is expected to expire on April 11, 2025, based on the standard 20-year term from the filing date.
-
Does this patent protect compounds that are not structurally defined within its claims?
The patent's protection is specifically limited to the chemical structures and methods described and claimed within its text. Compounds falling outside these defined structures would not be covered by this patent.
-
Are there any known products currently marketed in Japan that are directly derived from JP2008511550?
This analysis does not provide direct information on specific marketed products linked to JP2008511550. Market clearance and commercialization depend on regulatory approvals and competitive patent positions.
-
What are the primary safety concerns historically associated with COX-2 inhibitors that this patent likely aims to address?
The primary safety concerns have been related to increased cardiovascular risk (e.g., heart attack, stroke) and gastrointestinal complications, although selective COX-2 inhibitors were developed to reduce the latter.
-
Can a company develop and market a generic version of a drug based on JP2008511550 in Japan immediately after its expiry?
While a company can plan for generic market entry upon patent expiry, it must also ensure it does not infringe on any other active patents covering different aspects of the drug, such as formulation or manufacturing processes, and must obtain necessary regulatory approvals from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
Citations
[1] Merck & Co., Inc. (2008). Novel therapeutic agents for the treatment of inflammation, pain and fever. JP2008511550. Japan Patent Office.
